ROSEN, A GLOBAL INVESTOR RIGHTS LAW FIRM, ADVOCATES FOR ALLOVIR, INC. SHAREHOLDERS TO ACT BEFORE DEADLINE IN CLASS ACTION LAWSUIT

Investors who acquired AlloVir, Inc. ALVR securities during the period from March 22, 2022, to December 21, 2023, are now facing a critical deadline. ROSEN, a top-ranked investor counsel, has issued an alert for AlloVir investors to secure legal counsel prior to the looming March 19, 2024 cut-off date concerning a pending securities class action lawsuit.

AlloVir, Inc. - Company Overview

Based in Cambridge, Massachusetts, AlloVir, Inc. ALVR is a clinical-stage cell therapy company. It is spearheading the discovery and development of novel multi-virus-specific allogeneic T-cell therapies. These therapies are designed to defeat several virus-associated diseases in a preemptive and therapeutic manner, marking significant strides in medical biotechnology.

Securities Class Action: A Spotlight

ROSEN Law Firm, serving the global investor community, seeks to remind the investors holding shares of AlloVir during what is termed as the 'Class Period' – encompassing March 22, 2022 through December 21, 2023 – of the impending deadline to file a lead plaintiff motion in the class action lawsuit. The reminder specifies that any investor who wishes to participate in the lawsuit must move court by March 19, 2024. Such actions aim to protect investors' rights and recover damages due to potential violations of securities law.

ROSEN, AlloVir, Deadline